Cargando…

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas

Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory disease or experience lymphoma relapse. Chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pytlik, Robert, Polgarova, Kamila, Karolova, Jana, Klener, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768428/ https://www.ncbi.nlm.nih.gov/pubmed/33260966 http://dx.doi.org/10.3390/vaccines8040708

Ejemplares similares

Drug Resistance in Non-Hodgkin Lymphomas
por: Klener, Pavel, et al.
Publicado: (2020)

Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience
por: Polgárová, Kamila, et al.
Publicado: (2022)

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2020)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
por: Poggio, Teresa, et al.
Publicado: (2018)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Current approaches to the treatment of non-Hodgkin's lymphoma
por: Gisselbrecht, Christian
Publicado: (2011)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment
por: Watanabe, Takashi
Publicado: (2021)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2019)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021)

Surgery for Non-Hodgkin’s Lymphoma
por: Weledji, Elroy Patrick, et al.
Publicado: (2015)

Epidemiology of Non-Hodgkin’s Lymphoma
por: Thandra, Krishna C., et al.
Publicado: (2021)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
por: Parente, Paola, et al.
Publicado: (2020)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
por: Grover, Natalie S., et al.
Publicado: (2015)

Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
por: Jakša, Radek, et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Current advances in Hodgkin’s lymphoma
por: Vadakara, Joseph, et al.
Publicado: (2019)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
por: Renner, Christoph, et al.
Publicado: (2018)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Non-Coding RNAs in Hodgkin Lymphoma
por: Cordeiro, Anna, et al.
Publicado: (2017)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
por: Momotow, Jesko, et al.
Publicado: (2021)

Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma
por: Casagrande, Naike, et al.
Publicado: (2022)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

Non-Hodgkin's lymphoma: A review
por: Singh, Rohit, et al.
Publicado: (2020)

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
por: Hanel, Walter, et al.
Publicado: (2022)

Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas
por: Loni, L, et al.
Publicado: (2001)

SNPs Array Karyotyping in Non-Hodgkin Lymphoma
por: Etebari, Maryam, et al.
Publicado: (2015)

Systematic review of perchloroethylene and non-Hodgkin's lymphoma
por: Goodman, Julie E., et al.
Publicado: (2022)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Current Understanding of Lifestyle and Environmental Factors and Risk of Non-Hodgkin Lymphoma: An Epidemiological Update
por: Bassig, Bryan A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bm197vo8vq50339na78ffr7c3p